PFE Stock Analysis — Pfizer Inc.
Sector: Healthcare
AI Verdict
Pfizer is cheap for the growth you're getting at 8.5x forward earnings, but the market is clearly skeptical that the triple-digit EPS rebound will actually show up.
Competitive Moat
Pfizer's moat comes from its deep patent portfolio and global scale in drug manufacturing and distribution, which allows it to bring blockbuster drugs to market and defend them with regulatory exclusivity. Its R&D engine and established regulatory relationships make it difficult for smaller firms to compete at scale.
Summary
Pfizer's forward P/E of 8.5x and analyst consensus for 117.8% EPS growth make it a rare big pharma stock with both low valuation and a sharp earnings rebound expected.
Where It Stands
With a 1-year return of -4.18%, an RSI of 28.4 (deeply oversold), and a forward P/E of 8.5x versus the sector median of 22x, sentiment is washed out even as earnings are set to rebound.
Key Metrics
- RSI: 28.4 — Oversold
- Trailing P/E: 18.6x
- Forward P/E: 8.5x
- PEG Ratio: 0.16
- Earnings Growth: +1.2%
- Revenue Growth: +0.0%
- Market Cap: $138.6B
- Dividend Yield: 0.07%
- 1-Year Return: -4.18%
- 52-Week High: $28.75
- 52-Week Low: $23.11
Analyst Consensus
15 Buy · 18 Hold · 3 Sell (36 analysts) · Target $26.50
Bull Case
Pfizer trades at just 8.5x next year's earnings while analysts expect EPS to more than double (+117.8%), making it cheap for the growth on offer if those numbers materialize.
Bear Case
If the forward P/E reverts to the sector median of 22x only after earnings disappoint, the stock could stay stuck or even fall further despite the oversold RSI of 28.4.
Catalyst to Watch
Watch for upcoming drug approvals or clinical trial results — a major positive readout could validate the 117.8% EPS growth forecast and re-rate the stock.